Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT +7.90%66 Market Cap is $458.89 Mil as of Aug. 12, 2026. GuruFocus rates SGHT with a GF Score™ of 66/100 and a GF Value™ of $4.59 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 861 Medical Devices & Instruments companies, Sight Sciences ranks better than 66.32% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sight Sciences's share price for the quarter that ended in Jun. 2026 was $5.42. Sight Sciences's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 54.51 Mil. Therefore, Sight Sciences's market cap for the quarter that ended in Jun. 2026 was $295.42 Mil.
Sight Sciences's quarterly market cap
declined
from Dec. 2025 ($424.21 Mil) to Mar. 2026 ($203.71 Mil) but then
increased
from Mar. 2026 ($203.71 Mil) to Jun. 2026 ($295.42 Mil).
Sight Sciences's annual market cap
declined
from Dec. 2023 ($253.52 Mil) to Dec. 2024 ($185.41 Mil) but then
increased
from Dec. 2024 ($185.41 Mil) to Dec. 2025 ($424.21 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sight Sciences's Enterprise Value for Today is $421.11 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sight Sciences Market Cap Related Terms
Sight Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sight Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Market Cap of $458.89 Mil as of Aug. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #290 out of 861 companies in the Medical Devices & Instruments industry, placing it in the top 33.7%.
Is Sight Sciences' Market Cap too high?
Sight Sciences' current Market Cap is $458.89 Mil. The Medical Devices & Instruments industry median Market Cap is 120.82. Sight Sciences' value of $458.89 Mil is 279.8% above this industry median. Based on the distribution chart, Sight Sciences ranks #290 out of 861 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sight Sciences has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Market Cap compare to TMCI and TLSI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #290 out of 861 companies for Market Cap. This puts Sight Sciences in the upper half of its industry. The industry median Market Cap is 120.82. Sight Sciences' value of $458.89 Mil is 279.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.82, based on 861 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Market Cap of $458.89 Mil is 279.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Market Cap is $458.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.59, compared to a current price of $8.33 — trading 81.5% above its estimated fair value. The current Market Cap is $458.89 Mil and 279.8% above the Medical Devices & Instruments industry median of 120.82. Sight Sciences' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Market Cap is $458.89 Mil as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $8.33 is trading 81.5% above its estimated GF Value™ of $4.59.
GuruFocus considers Sight Sciences to be Significantly Overvalued.
Key valuation signals for SGHT:
Market Cap: $458.89 Mil
GF Value™: $4.59 vs. price of $8.33 (81.5% above fair value)
Industry Position: 279.8% above the Medical Devices & Instruments median (#290 of 861)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
66GF Score
Get the complete analysis for SGHT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
